PMDA drug package insert
ゼップバウンド皮下注2.5mgアテオス
PMDA Prescription drug · 日本イーライリリー株式会社 · package insert Sep 15, 2026
Key facts
| Brand names | ゼップバウンド皮下注2.5mgアテオス, ゼップバウンド皮下注5mgアテオス, ゼップバウンド皮下注7.5mgアテオス, ゼップバウンド皮下注10mgアテオス, ゼップバウンド皮下注12.5mgアテオス, ゼップバウンド皮下注15mgアテオス |
|---|---|
| Nonproprietary names | チルゼパチド |
| Companies | 製造販売元／日本イーライリリー株式会社, 販売元／田辺ファーマ株式会社 |
| Product type | Prescription drug |
| Therapeutic category | 持続性GIP/GLP-1受容体作動薬 |
| Therapeutic category codes | 872499 |
| YJ codes | 2499422G7022, 2499422G8029, 2499422G9025, 2499422P1024, 2499422P2020, 2499422P3027 |
| Approval numbers | 30600AMX00288, 30600AMX00289, 30600AMX00290, 30600AMX00291, 30600AMX00292, 30600AMX00293 |
| Package insert edition | 第6版 |
| Package insert date | Sep 15, 2026 |
| PMDA document key | 530471_2499422G7022_1 |
| PMDA company code | 530471 |
At a glance
- 1–9 Package insert revisions
- 10–99 Related PMDA documents
- None Safety communications
- Yes PMDA review report published
- Yes Risk management plan (RMP)
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About PMDA approved drugs and package inserts (Japan)
Japan's PMDA publishes the package insert (添付文書) of every prescription drug, OTC drug and regenerative medical product, with brand and nonproprietary names, YJ codes and approval numbers. Names appear in Japanese as published.
Source: Pharmaceuticals and Medical Devices Agency (PMDA), Japan, package insert database · Source date: